Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

The purpose of this Phase 1, randomized, open-label, two-period crossover study is to characterize and compare the pharmacokinetic (PK) profiles and evaluate the safety of the AG-348 tablet and capsule formulations after single-dose administration in healthy adult subjects. Pharmacokinetic sampling will take place serially at specified times during conduct of the study.

Key facts

Study ID

NCT03397329

Run by

Agios Pharmaceuticals, Inc.

People needed

26

Starts

2017-10-03

Expected to finish

2017-11-13

Last updated by the study team

2018-01-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Be a male or female aged 18 to 55 years, inclusive.
• Have a body mass index (BMI) of ≥ 18.5 to ≤ 29.0 kg/m2 at Screening.
• Agrees to abstain from any alcohol consumption.
• Be healthy overall with no clinically significant medical abnormalities, as determined by the Investigator through evaluation of the subject's medical history and Screening vital signs, ECG, physical examination, and laboratory assessments.

You may not qualify if…

• Have undergone any major surgical procedure within the 3 months prior to Screening.
• Has at Screening or has had within the 12 months prior to Screening any significant illness.
• Test positive at Screening for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus (HIV).
• Have a Screening systolic blood pressure (BP) reading of ≥140 mmHg (≥150 mmHg in subjects >45 years of age) OR a diastolic BP reading of ≥90 mmHg.
• Has any history of drug or alcohol abuse within the 2 years prior to Screening.
• Is a current smoker or user of any other tobacco product.
• Have had, including by voluntary donation, > 400 mL of blood collected within the 3 months prior to Screening.
• Have taken within the 14 days prior to study drug dosing any prescription medication, over-the counter medication, or nonprescription preparation-including vitamins, minerals, phytotherapeutic/herbal/plant-derived preparations, or grapefruit juice-unless deemed acceptable by the Investigator OR have taken within the 28 days prior to study drug dosing any restricted product known to strongly induce CYP3A4 metabolism (eg, St. John's Wort).
• Have participated in another clinical research study within the 3 months prior to Screening.

Where it is running

• Covance Clinical Research Unit, Inc. — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.